Chartwell Investment Partners LLC grew its position in Teleflex Incorporated (NYSE:TFX) by 3.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,444 shares of the medical technology company’s stock after purchasing an additional 204 shares during the period. Chartwell Investment Partners LLC’s holdings in Teleflex were worth $1,317,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Toronto Dominion Bank boosted its stake in shares of Teleflex by 14.5% in the 2nd quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 70 shares in the last quarter. Advisory Services Network LLC boosted its stake in shares of Teleflex by 933.8% in the 2nd quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock valued at $172,000 after purchasing an additional 747 shares in the last quarter. Cornerstone Capital Management Holdings LLC. acquired a new stake in shares of Teleflex in the 2nd quarter valued at $175,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Teleflex in the 2nd quarter valued at $200,000. Finally, Calamos Advisors LLC acquired a new stake in shares of Teleflex in the 2nd quarter valued at $206,000. Institutional investors own 89.11% of the company’s stock.
Shares of Teleflex Incorporated (NYSE TFX) traded up $1.15 during midday trading on Friday, reaching $267.71. 55,306 shares of the company traded hands, compared to its average volume of 280,456. The firm has a market cap of $12,060.07, a P/E ratio of 33.09, a price-to-earnings-growth ratio of 2.29 and a beta of 1.05. The company has a current ratio of 4.72, a quick ratio of 3.70 and a debt-to-equity ratio of 0.88. Teleflex Incorporated has a 1-year low of $142.97 and a 1-year high of $269.78.
Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.01 by $0.11. The business had revenue of $534.70 million for the quarter, compared to the consensus estimate of $522.94 million. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. The firm’s quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.80 EPS. research analysts predict that Teleflex Incorporated will post 8.35 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Wednesday, November 15th will be given a dividend of $0.34 per share. The ex-dividend date is Tuesday, November 14th. This represents a $1.36 annualized dividend and a yield of 0.51%. Teleflex’s dividend payout ratio (DPR) is 24.82%.
In related news, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $211.75, for a total transaction of $42,350.00. Following the transaction, the director now owns 8,080 shares in the company, valued at approximately $1,710,940. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 600 shares of company stock worth $138,162. 2.39% of the stock is owned by corporate insiders.
Several brokerages have recently commented on TFX. Jefferies Group LLC boosted their target price on shares of Teleflex from $270.00 to $295.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Morgan Stanley boosted their target price on shares of Teleflex from $274.00 to $290.00 and gave the company an “equal weight” rating in a research note on Friday, November 3rd. Piper Jaffray Companies began coverage on shares of Teleflex in a research note on Friday, November 10th. They issued an “overweight” rating and a $295.00 target price on the stock. Deutsche Bank AG downgraded shares of Teleflex from a “buy” rating to a “hold” rating and set a $251.00 target price on the stock. in a research note on Tuesday, November 14th. Finally, Needham & Company LLC boosted their target price on shares of Teleflex from $237.00 to $285.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. Teleflex currently has a consensus rating of “Hold” and an average price target of $274.44.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.